ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight's gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. BofA Securities acted as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan also acted as bookrunning manager for the offering. BTIG acted as co-manager of the offering. RxSight filed an automatic shelf registration ...